Contineum Therapeutics, Inc. CTNM
Biotechnology: Pharmaceutical Preparations · IPO 2024 · data as of November 13, 2026
Contineum Therapeutics, Inc. (CTNM) is a healthcare company listed in the US with a market value of about $387M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -25%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 27% below the current price.
About Contineum Therapeutics
Contineum Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2024. It was profitable in 1 of the last 3 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | — | $0 | $50M |
| Net income | -$60M | -$42M | $23M |
| Free cash flow | -$56M | -$33M | $19M |
| EPS (diluted) | $-2.17 | $-2.18 | $0.08 |
| Net margin | — | — | 45.4% |
| ROIC | -25.3% | -24.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $21.43, 117% above the current price; targets range from $14.00 to $30.00; the consensus rating is “Buy”; expected EPS is $-1.78 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Contineum Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 27% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Contineum Therapeutics pay a dividend?
Not currently.
Is Contineum Therapeutics a good stock to buy?
We do not give buy or sell advice. Contineum Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.